| Source: |
Mouse myeloma cell line, NS0 |
| Molecular Weight: |
Apparent molecular mass of 24 kDa in SDS-PAGE under non-reducing conditions, 12 kDa under reducing conditions, a disulfide-linked homodimer of two 112 amino acid glycosylated polypeptide chains. |
| AA Sequence: |
Ala303-Ser414; Accession # P61812 |
| Purity: |
> 97% by SDS-PAGE analyses. |
| Biological Activity: |
Measured by its ability to inhibit the IL-4-dependent proliferation of HT‑2 mouse T cells. The ED50 for this effect is 0.025-0.25 ng/mL. |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from 0.2 µm filtered concentrated solution in 35% Acetonitrile and 0.1% TFA. |
| Endotoxin: |
Less than 0.1 EU/µg of rHuTGF-β2 as determined by LAL method. |
| Reconstitution: |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile 4 mM HCl to a concentration of 0.1 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriately buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Background: |
TGF-β2 is a versatile cytokine involved in the regulation of immune functions, cellular proliferation, and epithelial-mesenchymal transition. It plays a critical role in the development of various systems across species, including cardiac, lung, craniofacial, limb, eye, ear, and urogenital systems. The activation of latent TGF-β2 occurs through proteolytic cleavage that releases the mature cytokine from the latency-associated peptide. The signaling pathway of TGF-β2 requires the accessory receptor Betaglycan, TGF-β RII, and a type I TGF-β receptor, ultimately activating Smad signal transduction. |
